Core Insights - Blade Air Mobility, Inc. reported a 4.2% increase in revenue to $70.8 million for Q2 2025 compared to $67.9 million in Q2 2024, driven primarily by growth in the Medical segment [9][12] - The company announced the sale of its Passenger division to Joby Aviation for up to $125 million, while the Medical division will remain a standalone public company, rebranding as Strata Critical Medical [6][8] - Net loss improved significantly by $7.6 million year-over-year to $(3.7) million in Q2 2025, with Adjusted EBITDA increasing by $2.2 million to $3.2 million [6][14] Financial Results - Total revenue for the six months ended June 30, 2025, was $125.1 million, up 4.7% from $119.5 million in the same period of 2024 [3][9] - Cost of revenue increased by 2.9% to $53.1 million in Q2 2025, while total operating expenses decreased by 5.4% to $75.8 million [3][9] - Gross profit rose to $12.9 million in Q2 2025, reflecting a gross margin improvement to 18.2% from 16.7% in Q2 2024 [3][9] Segment Performance - Medical revenue increased by 17.6% year-over-year to $45.1 million in Q2 2025, while Passenger segment revenue decreased by 13.2% to $25.7 million [9][35] - Flight profit for the Medical segment was $9.9 million, with a flight margin of 22.0%, while the Passenger segment achieved a flight profit of $7.8 million and a flight margin of 30.5% [39][40] - The company reported a decrease in Short Distance revenue by 17.8% to $17.2 million, attributed to reduced demand following a helicopter incident and inclement weather [9][14] Strategic Updates - The divestiture of the Passenger division is expected to be neutral to Adjusted EBITDA and Free Cash Flow on a go-forward basis, supported by estimated corporate cost efficiencies of approximately $7 million [9][12] - Blade's Medical division will focus on contractual healthcare solutions with no direct reimbursement risk, aiming for a strong growth profile [8][9] - The company ended Q2 2025 with $113.4 million in cash and short-term investments, positioning itself for future growth and strategic investments [14][12]

Financial Highlights - FY 2024 revenue reached $249 million, showing a year-over-year growth of 10%[6] - Medical revenue for FY 2024 was $147 million, with a year-over-year growth of 16%[6] - Adjusted EBITDA improved by $178 million year-over-year in FY 2024[6] - Q1 2025 revenue was $54 million, reflecting a 10% year-over-year growth excluding Canada[6] - Passenger revenue in Q1 2025 was $18 million, showing a 42% year-over-year increase excluding Canada[6] - Adjusted EBITDA improved by $23 million year-over-year in Q1 2025[6] Medical Segment - Medical segment revenue for the trailing twelve months ending March 31, 2025, was $147 million, an 8% year-over-year growth[11] - Medical segment adjusted EBITDA for the same period was $19 million, with a 25% year-over-year growth[11] - Flight Profit for the medical segment was $33 million, with a 22% margin and 25% year-over-year growth[11] Passenger Segment - Passenger segment revenue for the trailing twelve months ending March 31, 2025, was $105 million, a 10% year-over-year growth, or 42% excluding Canada[11] - Passenger segment adjusted EBITDA for the same period was $63 million, with a $109 million growth year-over-year[11] - Flight Profit for the passenger segment was $28 million, with a 27% margin and 48% year-over-year growth[11] Organ Transplant - From 2018 to 2024, heart, liver, and lung transplant distances increased by 64%[42] Ground Transport - Blade Medical's ground transport annualized revenue is approximately $20 million[50]

Company Overview - Blade Air Mobility, Inc. is a provider of air transportation and logistics services, primarily for hospitals in the United States, and is one of the largest transporters of human organs for transplant [3] - The company offers helicopter and fixed-wing services mainly in the Northeast United States and Southern Europe, operating an asset-light model with exclusive passenger terminal infrastructure and proprietary technologies [3] Financial Results Announcement - Blade will release its financial results for the first quarter ended March 31, 2025, on May 12, 2025, before the market opens [1] - A conference call will be held on the same day at 8:00 am Eastern Time, hosted by the CEO Rob Wiesenthal and CFO Will Heyburn, including a question-and-answer session [1][2] Business Model and Technology - Blade's business model is designed to facilitate a seamless transition from traditional air transport to Electric Vertical Aircraft (EVA or eVTOL), aiming for lower-cost, quiet, and emission-free air mobility [3]